Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
November 17, 2016Ryan Chavez Appointed Chief Financial Officer of Asterias Biotherapeutics
FREMONT, Calif., Nov. 17, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced the appointment of Ryan Chavez to the position of Chief Financial Officer. In his expanded role, Mr. Chavez, who will also retain the title of General Counsel, will oversee all financial aspects of the company. Mr. Chavez will continue to report to Asterias' President and Chief Executive Officer Steve Cartt. Mr. Chav... 
Printer Friendly Version
November 14, 2016Asterias Biotherapeutics Reports Third Quarter Results and Accelerating Enrollment of AST-OPC1 SCiStar Phase 1/2a Study
-Study enrollment has recently accelerated, with three patients dosed in past week- -Achievement of enrollment milestone meets requirement for an additional $2.5 million grant payment to Asterias from the California Institute for Regenerative Medicine- -SCiStar investigator and patient will discuss experiences with AST-OPC1 on call today at 4:30 p.m. Eastern / 1:30 p.m. Pacific- FREMONT, Calif., Nov. 14, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnolog... 
Printer Friendly Version
November 14, 2016OncoCyte Announces Publication of Breast Cancer Diagnostic Test Abstract; Poster to be Presented at the San Antonio Breast Cancer Symposium on December 9, 2016
Study results in encouraging AUC ROC score of .92, follow up study underway ALAMEDA, Calif., Nov. 14, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, provided a summary of the data from its breast cancer diagnostic test that will be presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) in December.  The data will be presented by Karen B. Chapman, Ph.D., OncoCyte’s Vice President of Research, ... 
Printer Friendly Version
November 10, 2016OncoCyte Reports Third Quarter 2016 Financial Results
Currently Processing Samples and Analyzing Results in its Lung Cancer Test Study; Continues to Project a Completion Date in Late December Conference Call to Discuss the Results at 5:00 p.m. ET ALAMEDA, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today reported its financial results for the third quarter ended September 30, 2016 along with an update on recent corporate ... 
Printer Friendly Version
November 08, 2016OncoCyte Promotes Lyndal Hesterberg to Senior Vice President, Research and Development
ALAMEDA, Calif., Nov. 08, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests for the early detection of cancer, today announced that Lyndal Hesterberg, Ph.D. has been promoted to Senior Vice President, Research and Development, a newly created position reporting to William Annett, OncoCyte’s Chief Executive Officer. In his new role, Dr. Hesterberg will oversee the Company’s research, development, clinical and regulatory teams.  ... 
Printer Friendly Version
November 08, 2016Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial
-Complete cervical spinal cord injury patient (AIS-A) has for the first time received maximum 20 million cell dose of AST-OPC1- -Enrollment and dosing of patients with incomplete cervical spinal cord injuries (AIS-B) continues; second AIS-B patient recently dosed with 10 million cells- FREMONT, Calif., Nov. 8, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the first patient wit... 
Printer Friendly Version
November 04, 2016Asterias Biotherapeutics to Report Third Quarter Results on November 14, 2016
-SCiSTAR Investigator and Patient Will Join Call to Discuss Experiences with AST-OPC1- FREMONT, Calif., Nov. 4, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that it will release third quarter financial results and provide an update on clinical progress on Monday, November 14, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast o... 
Printer Friendly Version
November 02, 2016UPDATE -- OncoCyte to Report Third Quarter Financial Results on November 10, 2016
ALAMEDA, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended September 30, 2016 on Thursday, November 10, 2016 after the close of the U.S. financial markets. The Company will host a conference call on Thursday, November 10, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results along... 
Printer Friendly Version
November 02, 2016OncoCyte to Report Third Quarter Financial Results on November 10, 2016
ALAMEDA, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended September 30, 2016 on Thursday, November 10, 2016 after the close of the U.S. financial markets. The Company will host a conference call on Thursday, November 10, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results along wit... 
Printer Friendly Version
October 24, 2016OncoCyte Announces Sponsored Symposium at the 2016 American College of Chest Physician’s CHEST 2016 Annual Meeting
ALAMEDA, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests for the detection of cancer, today announced that it will be sponsoring a symposium at the American College of Chest Physician’s 2016 CHEST Annual Meeting, being held in Los Angeles from October 22-26. The symposium is titled Lung Cancer Diagnosis-Challenges and Solutions and is scheduled for Monday, October 24th and will begin at 10:15am PT in the Exhibi... 
Printer Friendly Version
October 18, 2016LifeMap Solutions Joins Medidata AppConnect Partner Program to Drive mHealth Innovation
LifeMap Solutions to participate in annual Medidata Symposium, showcasing demo app that studies the effects of caffeine consumption with attendees SAN JOSE, Calif.--(BUSINESS WIRE)--Oct. 18, 2016-- LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX), today announced a partnership with Medidata (NASDAQ: MDSO), the leading provider of cloud-based solutions for clinical research. LifeMap is joining Medidata’s AppConn... 
Printer Friendly Version
October 17, 2016OncoCyte and The Wistar Institute Present Lung Cancer Diagnostic Data at the CHEST 2016 Annual Meeting
ALAMEDA, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood-based tests for the early detection of cancer, and The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announced a summary of the data that will be presented at the American College of Chest Physician’s CHEST 2016 Annual Meeting, which will be held October 22-26 in Los Angeles. The data will be presented by... 
Printer Friendly Version
October 14, 2016OncoCyte Corporation to Present at the BIO Investor Forum
ALAMEDA, Calif., Oct. 14, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the BIO Investor Forum on Wednesday, October 19, 2016 at 4:30 p.m. ET / 1:30 p.m. PT.   The conference will be held at the Westin St. Francis Hotel in San Francisco. A live webcast and subsequent ar... 
Printer Friendly Version
September 27, 2016Asterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 in an Expanded Cervical Spinal Cord Injury Patient Population
-First dosing in SCiSTAR study of an AIS-B patient, characterized as having complete loss of movement while still retaining some sensory function below the cervical injury site- -Patient received 10 million cell dose of AST-OPC1- FREMONT, Calif., Sept. 27, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced that the first patient with incomplete AIS-B cervical spinal cord injury was succ... 
Printer Friendly Version
September 20, 2016OncoCyte Corporation to Present at the 2016 Aegis Growth Conference
ALAMEDA, Calif., Sept. 20, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the 2016 Aegis Growth Conference on Thursday, September 22, 2016 at 5:30 p.m. ET/ 2:30 p.m. PT.   The conference will be held at the Encore at Wynn Hotel in Las Vegas. A live webcast and subsequent... 
Printer Friendly Version
September 17, 2016Asterias Biotherapeutics Announces Interim Efficacy Data from SCiStar Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury Patients to be Presented at the 55th ISCoS Annual Scientific Meeting
-Asterias to Host Conference Call to Discuss Data on September 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific- FREMONT, Calif., Sept. 7, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today announced that Edward Wirth, MD, PhD, Chief Medical Officer, will present interim efficacy data from the 10 million cell cohort in the company's ongoing AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients on Wednesday, September 14, 2016. The... 
Printer Friendly Version
September 17, 2016Asterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients
-Data Monitoring Committee (DMC) concludes that the favorable safety profile observed in the study supports plan for significant dose increase- -Newly enrolled complete cervical spinal cord injury patients will now receive the highest AST-OPC1 dose of 20 million cells- FREMONT, Calif., Aug. 31, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committe... 
Printer Friendly Version
September 15, 2016BioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With Complete Cervical Spinal Cord Injuries
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 15, 2016-- BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that its affiliate, Asterias Biotherapeutics, announced positive interim efficacy data from the AST-OPC1 SCiSTAR Phase 1/2a clinical study in patients with complete cervical spinal cord injuries at the 55th Annual Scientific Meeting of the International Spinal Cord... 
Printer Friendly Version
September 14, 2016Asterias Biotherapeutics Announces Positive Efficacy Data in Patients with Complete Cervical Spinal Cord Injuries Treated with AST-OPC1
-Cohort of SCiSTAR trial patients with complete cervical spinal cord injuries reaches the targeted 6-12 month efficacy endpoint within 3 months- -Dose response based on number of AST-OPC1 cells administered appears to be emerging- -Asterias to Host Conference Call Today at 4:30pm ET to Discuss Efficacy Data Presented at the 55th Annual Scientific Meeting of the International Spinal Cord Society- FREMONT, Calif., Sept. 14, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AS... 
Printer Friendly Version
September 13, 2016Asterias Biotherapeutics Announces AST-OPC1 SCiSTAR Study Investigator Charles Y. Liu, MD, PhD, and Director, USC Neurorestoration Center, to Discuss Interim Data on Conference Call on September 14, 2016
FREMONT, Calif., Sept. 13, 2016 /PRNewswire/ -- Asterias Biotherapeutics (NYSE MKT: AST) announced today that Charles Y. Liu, MD, PhD, Director, USC Neurorestoration Center and investigator on the AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients, will participate on the company's conference call on Wednesday, September 14, 2016. Dr. Liu will discuss interim efficacy data observed in patients from the 10 million cell cohort in the ongoing SCiSTAR study. ... 
Printer Friendly Version
September 12, 2016Asterias Biotherapeutics to Present at Rodman & Renshaw Annual Global Investment Conference Today, September 12, 2016, in Advance of Upcoming Interim Efficacy Data Release from Spinal Cord Injury Trial
FREMONT, Calif., Sept. 12, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, announced that Steve Cartt, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference today, Monday, September 12, 2016 at 5:05 PM Eastern Time at The Lotte New York Palace Hotel.  A live webcast of the presentation will be accessible at http://asteriasbiotherapeut... 
Printer Friendly Version
September 08, 2016OncoCyte to Present Initial Data on its Breast Cancer Diagnostic Test at the Prestigious San Antonio Breast Cancer Symposium
Poster Presentation on December 9, 2016 at 5:00pm CT ALAMEDA, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced that its breast cancer abstract has been selected for presentation in a poster session, at the 2016 San Antonio Breast Cancer Symposium (SABCS) in December at the Henry B. Gonzalez Convention Center in San Antonio, TX. Each year the current standard of care for the ... 
Printer Friendly Version
September 07, 2016Asterias Biotherapeutics Announces Interim Efficacy Data from SCiStar Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury Patients to be Presented at the 55th ISCoS Annual Scientific Meeting
-Asterias to Host Conference Call to Discuss Data on September 14, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific- FREMONT, Calif., Sept. 7, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), today announced that Edward Wirth, MD, PhD, Chief Medical Officer, will present interim efficacy data from the 10 million cell cohort in the company's ongoing AST-OPC1 SCiSTAR Phase 1/2a clinical study in complete cervical spinal cord injury patients on Wednesday, September 14, 2016. The... 
Printer Friendly Version
September 07, 2016OncoCyte Corporation to Present at the Annual Gateway Conference
ALAMEDA, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE:OCX), a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett, Chief Executive Officer, is scheduled to present an overview of the Company and its progress at the Annual Gateway Conference on Thursday, September 8, 2016 at 3:30 p.m. ET / 12:30 p.m. PT.   The conference will be held at the Four Seasons Hotel in San Francisco. A live webcast and subsequent arc... 
Printer Friendly Version
August 31, 2016Asterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients
-Data Monitoring Committee (DMC) concludes that the favorable safety profile observed in the study supports plan for significant dose increase- -Newly enrolled complete cervical spinal cord injury patients will now receive the highest AST-OPC1 dose of 20 million cells- FREMONT, Calif., Aug. 31, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committe... 
Printer Friendly Version
August 29, 2016Don M. Bailey Appointed to OncoCyte Corporation’s Board of Directors
Experienced Senior Executive with Track Record of Consistently and Rapidly Building Shareholder Value at Several Companies Makes Equity Investment in OncoCyte ALAMEDA, Calif., Aug. 29, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood and urine based tests for the early detection of cancer, today announced the appointment of Don M. Bailey to the Company’s Board of Directors. Mr. Bailey will also be making a $750,000 investment in OncoCyte a... 
Printer Friendly Version
August 29, 2016OncoCyte Corporation Announces the Closing of Two Private Placement Transactions Generating Gross Proceeds of $10.55 Million
Net Proceeds to be Used to Continue R&D of Non-Invasive Cancer Diagnostics Tests and CLIA Compliant Laboratory Build-Out ALAMEDA, Calif., Aug. 29, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it has closed two separate private placements with a select group of institutional and accredited investors, including both new and existing investors. The private placements ... 
Printer Friendly Version
August 15, 2016Asterias Biotherapeutics Reports Second Quarter Results and Highlights Progress of SCiSTAR Study Evaluating AST-OPC1 in Spinal Cord Injury Patients
FREMONT, Calif., Aug. 15, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today reported financial results for the second quarter ended June 30, 2016 and recent highlights.  The company continued to achieve notable clinical progress with AST-OPC1, its experimental treatment derived from pluripotent stem cells for spinal cord injury.  Up to this point... 
Printer Friendly Version
August 01, 2016Asterias Biotherapeutics to Report Second Quarter Results on August 15, 2016
FREMONT, Calif., Aug. 1, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it will release second quarter financial and operating results on Monday, August 15, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on August 15, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discus... 
Printer Friendly Version
July 27, 2016OncoCyte and The Wistar Institute Announce Presentation of Lung Data at CHEST 2016 Annual Meeting
ALAMEDA, Calif., July 27, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, and The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, today announce that research results for a lung cancer diagnostic test being developed by The Wistar Institute and OncoCyte under a license from Wistar have been accepted for an Original Investigation Slid... 
Printer Friendly Version
July 21, 2016OncoCyte to Report Second Quarter Financial Results on August 11, 2016
ALAMEDA, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended June 30, 2016 on Thursday, August 11, 2016 after the close of the U.S. financial markets. The Company will host a conference call on Thursday, August 11, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results along with rec... 
Printer Friendly Version
July 18, 2016Asterias Biotherapeutics Appoints Ryan Chavez as EVP of Finance and General Counsel
FREMONT, Calif., July 18, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that the company has appointed Ryan Chavez as Executive Vice President of Finance and General Counsel, effective today, reporting to Steve Cartt, President and Chief Executive Officer.           As Asterias' chief legal officer and a senior financial executi... 
Printer Friendly Version
July 12, 2016Asterias Biotherapeutics Completes Enrollment and Dosing for the First Efficacy Cohort of the AST-OPC1 SCiSTAR Phase 1/2a Clinical Trial in Complete Cervical Spinal Cord Injury
- Expects to Announce Six-Month Results From This First Efficacy Cohort in January 2017- -Patient Motor Function Improvements Observed in Earlier Very Low Dose Safety Cohort- FREMONT, Calif., July 12, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced completion of enrollment and dosing of five patients in the first efficacy cohort... 
Printer Friendly Version
June 28, 2016Mount Sinai Launches Mobile Healthcare App Developed with LifeMap Solutions, a subsidiary of BioTime
New York, NY – June 28, 2016 /Press Release/ –– Mount Sinai Health System (MSHS) today announced the launch of a new mobile application for patients called MountSinaiNY. Developed by Mount Sinai’s Department of Information Technology, MountSinaiNY will serve as a one-touch patient experience, featuring centralized information and services that provide greater access to and utilization of health services offered at the Health System.“The MountSinaiNY app is a digital gateway to the many services... 
Printer Friendly Version
June 21, 2016Asterias Biotherapeutics Announces Oral Presentation and Participation in Panel Discussion at the ISSCR 14th Annual Meeting
-Oral presentation to review development of AST-OPC1 for spinal cord injury- -Panel discussion to focus on development of pluripotent stem cell therapies- FREMONT, Calif., June 21, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that a review of its AST-OPC1 (oligodendrocyte progenitor cells) spinal cord injury program will be p... 
Printer Friendly Version
June 06, 2016OncoCyte Presents Positive Bladder Cancer Diagnostic Data at the 2016 American Society of Clinical Oncology Annual Meeting
ALAMEDA, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive tests for the early detection of cancer, is presenting data today from a bladder cancer study featured as a poster and also highlighted during a live panel discussion during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The poster abstract, entitled Derivation of Gene Expression Classifiers for the Non-invasive Detection of B... 
Printer Friendly Version
May 24, 2016Asterias Biotherapeutics Announces Positive New Long-Term Follow-Up Results for AST-OPC1
-Data Included in Newly Submitted Patent Application for AST-OPC1- FREMONT, Calif., May 24, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced new positive long-term follow-up results from its Phase 1 clinical trial assessing the safety of AST-OPC1 (oligodendrocyte progenitor cells) in patients with spinal cord injury. The results sho... 
Printer Friendly Version
May 23, 2016Asterias Biotherapeutics Closes Exercise of Over-Allotment Option in Connection with its Previously Announced Public Offering
FREMONT, Calif., May 23, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, announced today the closing of the exercise of the over-allotment option granted to the underwriters of its previously announced public offering. The underwriters purchased an additional 742,421 shares of Asterias' common stock. The exercise of the over-allotment option to purch... 
Printer Friendly Version
May 19, 2016OncoCyte to Release Bladder Cancer Data at the 2016 American Society of Clinical Oncology Annual Meeting
Positive New Data to be Featured in a Poster Discussion ALAMEDA, Calif., May 19, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive tests for the early detection of cancer, released today the abstract of data from a bladder cancer study that will be presented as a poster and also highlighted during a live panel discussion on June 6, 2016, during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Illinois. ... 
Printer Friendly Version
May 18, 2016OncoCyte Reports First Quarter 2016 Financial Results
Conference Call to Discuss the Results at 5 p.m. ET ALAMEDA, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, today reported its financial results for the quarter ended March 31, 2016 along with an update on recent corporate developments. “We achieved several important milestones during the first quarter, including initiating our first trade as a public company,” commented W... 
Printer Friendly Version
May 16, 2016Asterias Biotherapeutics Reports First Quarter Results
-FDA Clears Expansion of AST-OPC1 Clinical Trial in Spinal Cord Injury- -Capital Resources Now in Place to Fund AST-OPC1 Clinical Trial Expansion and Continue Progress on Cancer Immunotherapy Programs- -Conference Call and Webcast Today, May 16, at 4:30 p.m. ET- FREMONT, Calif., May 16, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today r... 
Printer Friendly Version
May 13, 2016Asterias Biotherapeutics Announces Closing of Public Offering of Common Stock and Warrants, and Exercise of Over-Allotment Option to Purchase Additional Warrants
FREMONT, Calif., May 13, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, announced today the closing of its previously announced underwritten public offering of 5,147,059 shares of common stock, and warrants to purchase an aggregate of 2,573,530 shares of common stock at an exercise price of $4.37 per share. The underwriters also exercised their over... 
Printer Friendly Version
May 12, 2016OncoCyte to Report First Quarter Financial Results on May 18, 2016
ALAMEDA, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that it will release its financial and operating results for the quarter ended March 31, 2016 on Wednesday, May 18, 2016 after the close of the U.S. financial markets . The Company will host a conference call on Wednesday, May 18, 2016 at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results along with recent... 
Printer Friendly Version
May 11, 2016Asterias Biotherapeutics to Report First Quarter Results on May 16, 2016
FREMONT, Calif., May 11, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it will release first quarter financial and operating results on Monday, May 16, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on May 16, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the r... 
Printer Friendly Version
May 10, 2016Asterias Biotherapeutics Prices Public Offering of Common Stock and Warrants
FREMONT, Calif., May 10, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced the pricing of an underwritten public offering of 5,147,059 units at a public offering price of $3.40 per unit. Each unit consists of one share of common stock and 0.5 of a warrant to purchase a share of common stock at an exercise price of $4.37 per share. The w... 
Printer Friendly Version
May 09, 2016Asterias Biotherapeutics Announces Proposed Public Offering
FREMONT, Calif., May 9, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. The shares of common stock and warrants to purchase shares of common stock are being offered as units. The shares of common ... 
Printer Friendly Version
May 06, 2016ReCyte Therapeutics, a BioTime Subsidiary, Announces Peer-Reviewed Publication on Pericyte-Like Progenitor Cells
New isolated cell line has the potential to address a critical unmet medical need for patients suffering from ischemic vascular diseaseALAMEDA, Calif.--(BUSINESS WIRE) -- May 6, 2016 -- ReCyte Therapeutics, a subsidiary of BioTime, Inc., a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced the publication of a scientific paper titled, “A novel lineage restricted, pericyte-like cell line isolated from human embryonic stem cells... 
Printer Friendly Version
May 02, 2016Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting
FREMONT, Calif., May 2, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that clinical data from its AST-VAC1 (antigen-presenting autologous dendritic cells) immunotherapy clinical program will be presented during an oral session at the upcoming American Society of Gene and Cell Therapy (ASGCT) 19th Annual Meeting, to be held on May 4-... 
Printer Friendly Version
April 28, 2016Howard I. Scher M.D., Leading Clinical Oncology Expert, Joins the Board of Directors of Asterias Biotherapeutics
FREMONT, Calif., April 28, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced the appointment of Howard I. Scher M.D., one of the world's leading oncology experts, to the Company's Board of Directors. Dr. Scher, 64, is internationally recognized for his expertise in clinical oncology. He has extensive experience in the design of clini... 
Printer Friendly Version
April 26, 2016Asterias Biotherapeutics to Present at Stem Cell Summit 2016
FREMONT, Calif., April 26, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with three clinical-stage development programs focused on the emerging field of regenerative medicine, today announced that Katharine Spink, Ph.D., Chief Operating Officer, will present at the Stem Cell Summit 2016 to be held on April 25-27, 2016 in Boston, MA. Dr. Spink will provide an overview of the Asterias AST-OPC1 (oligodendrocyte progenitor cells) therapeutic development... 
Printer Friendly Version
April 25, 2016LifeMap Solutions Launches Full-Service Mobile Health App Design & Development to Meet the Needs of Medical, Research, and Commercial Partners
Digital health solutions provider makes its ResearchKit and CareKit app expertise available to research institutions and health companies worldwide to advance insights into human health SAN JOSE, Calif.--(BUSINESS WIRE)--Apr. 25, 2016-- LifeMap Solutions, the digital health subsidiary of BioTime, Inc. (NYSE MKT: BTX) and co-developer of ResearchKit-enabled app Asthma Health, today announced a new service to develop custom smartphone apps and r... 
Printer Friendly Version
April 21, 2016OncoCyte’s Bladder Cancer Abstract to be Featured in a Poster Discussion Session at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Live Panel Discussion on June 6, 2016 at 4:45pm CT ALAMEDA, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that its bladder cancer abstract has been selected for presentation in a poster session, including a live panel discussion on the results, at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, Illinois June 3rd t... 
Printer Friendly Version
April 05, 2016BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK
Will Present on Novel Strategies for the Production of Diverse Pluripotent Stem Cell Types for Drug Discovery ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 5, 2016-- BioTime, Inc. (NYSE MKT: BTX) today announced that Co-Chief Executive Officer Michael D. West, Ph.D. will deliver a presentation at “Stem Cells in Drug Discovery 2016” on Wednesday, April 6 at 10:00 a.m. BST, in Cambridge, England. Dr. West’s presentation is titled, “Nove... 
Printer Friendly Version
March 31, 2016Asterias Biotherapeutics Announces Record Date for Distribution of Warrants to Holders of Asterias Series A Common Stock
FREMONT, Calif., March 31, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Board of Directors has set the record date for its distribution of 3,320,916 warrants to holders of its Series A common stock excluding BioTime, Inc. The Company has declared the record date for determination of stockholders eligible to participate in the warrant distribution as Monday, April 11, 2... 
Printer Friendly Version
March 29, 2016Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Reviews the Company's Three Clinical-Stage Cell Therapy Programs
Conference Call and Webcast Today, March 29, at 4:30 p.m. ET FREMONT, Calif., March 29, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today reported financial results for the fourth quarter and year ended December 31, 2015, as well as key corporate highlights. "Asterias has three promising clinical-stage therapeutic programs based on our immunotherapy and pluripotent stem cell platform te... 
Printer Friendly Version
March 23, 2016Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2015 Results on March 29, 2016
FREMONT, Calif., March 23, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that it will release fourth quarter and full year 2015 financial and operating results on Tuesday, March 29, 2016 after the close of the U.S. financial markets. The Company will host a conference call and webcast on March 29, 2016 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developme... 
Printer Friendly Version
February 29, 2016Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief Executive Officer
-- Don M. Bailey Appointed to Board of Directors and Named Chairman -- FREMONT, Calif., Feb. 29, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST) today announced the appointment of pharmaceutical industry veteran Stephen L. Cartt as President and Chief Executive Officer and member of the Board of Directors. In addition, the Company announced the appointment of Don M. Bailey to its Board of Directors. Mr. Bailey, who previously served as President and Chief Executive Officer... 
Printer Friendly Version
February 24, 2016Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1
- Provides Direction for Late-Stage Development of AST-VAC1 in Acute Myeloid Leukemia - FREMONT, Calif., Feb. 24, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE:AST) today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML). During the meeting, the FDA indicated general agreement with Asterias' proposed development plan for registration ... 
Printer Friendly Version
February 16, 2016Asterias Biotherapeutics Announces Intention to Distribute 3.15 Million Warrants to Purchase Common Shares of Asterias to Asterias Shareholders
FREMONT, Calif., Feb. 16, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today simplified its capital structure through the previously announced Asset Swap with BioTime, Inc. In conjunction with the Asset Swap, Asterias also announces its intention, at its discrestion, to distribute the 3.15 million warrants to purchase common shares of Asterias received pursuant to the Asset Sw... 
Printer Friendly Version
February 04, 2016Asterias Biotherapeutics Receives Orphan Drug Designation for AST-OPC1 for the Treatment of Acute Spinal Cord Injury
FREMONT, Calif., Feb. 4, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced receipt of Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its product development candidate, AST-OPC1, for the treatment of acute spinal cord injury. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to products that treat rare diseases. The F... 
Printer Friendly Version
February 02, 2016Asterias Biotherapeutics to Present at the 18th Annual BIO CEO & Investor Conference
FREMONT, Calif., Feb. 2, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced Katy Spink, Chief Operating Officer, will present at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 4:00 p.m. EST at the Waldorf Astoria Hotel in New York City. A live webcast and subsequent archived replay of the presentation will be accessible at http://asteriasbiothera... 
Printer Friendly Version
January 27, 2016OncoCyte Corporation and The Wistar Institute Enter into Global Licensing Agreement
Exclusive Rights to Commercialize Biomarker Assay Follows Years of Positive Collaboration on Lung Cancer Diagnostic Test ALAMEDA, Calif. and PHILADELPHIA, Jan. 27, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT: OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, and The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, have entered into a definitive global licensing agreement for a ... 
Printer Friendly Version
January 21, 2016Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial
FREMONT, Calif., Jan. 21, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), announced that it has completed the transfer of its manufacturing processes to produce AST-VAC2 to Cancer Research UK. AST-VAC2 is an innovative immunotherapy product that contains mature dendritic cells derived from pluripotent stem cells. These non-patient specific (allogeneic) AST-VAC2 cells are engineered to express a modified form of telomerase, a protein widely expressed in tumor cells, but r... 
Printer Friendly Version
January 20, 2016LifeMap Sciences, a Subsidiary of BioTime, Announces the Launch of TGex™, the Knowledge-Driven NGS Analysis Platform, Powered by the GeneCards Suite
ALAMEDA, Calif., January 20, 2016 – LifeMap Sciences, Inc. (“LifeMap”), a life sciences technology company and subsidiary of BioTime, Inc., announced today the market launch of TGex™ (Translational Genomics Expert), an integrated next-generation genomic sequencing (NGS) analysis platform. TGex™ leverages the GeneCards Suite Knowledgebase to rapidly identify genetic variants that may impact disease management and health outcomes, eliminating a traditional research bottleneck and enabling ... 
Printer Friendly Version
January 06, 2016Asterias Biotherapeutics to Present at Biotech Showcase™ 2016
FREMONT, Calif., Jan. 6, 2016 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that Pedro Lichtinger, President and CEO of Asterias, will present at the Biotech Showcase™ 2016 Conference in San Francisco on Tuesday, January 12, 2016 at 9:00 AM PT/12:00 PM ET. A live webcast and subsequent archived replay of the presentation will be accessible at http://asteriasbiotherapeutics.com/eve... 
Printer Friendly Version
January 04, 2016OncoCyte Corporation Initiates Trading on the NYSE MKT
Company’s Common Stock Listed Under the Symbol "OCX" beginning January 4, 2016 The Company Will Publish an Introductory Investor Webcast January 5, 2016 at 4 p.m. ETOncoCyte Scheduled to Ring the NYSE Opening Bell on Wednesday, January 6, 2016ALAMEDA, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a company focused on non-invasive cancer diagnostics, announced that its common stock is now trading on the NYSE MKT under the symbol "OCX."  The Company will ring... 
Printer Friendly Version